Barinthus Biotherapeutics (BRNS) Assets (2020 - 2026)
Barinthus Biotherapeutics' (BRNS) quarterly Assets came in at $92.1 million in Q1 2026, down 35.11% YoY from $142.0 million in Q1 2025, and down 6.14% on a QoQ basis from $98.2 million in Q4 2025.
Barinthus Biotherapeutics (BRNS) Assets (2020 - 2026) Analysis & Trends
Barinthus Biotherapeutics (BRNS) has 7 years of Assets data on file, last reported at $92.1 million in Q1 2026.
- Quarterly Assets fell 35.11% year-over-year to $92.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $92.1 million (down 35.11% YoY) and the FY2025 annual result came in at $98.2 million, down 38.77% from the prior year.
- Assets retreated to $92.1 million in Q1 2026, from $98.2 million in the prior quarter.
- In the past five years, Assets ranged from a high of $286.1 million in Q1 2022 to a low of $92.1 million in Q1 2026.
- A 5-year average of $198.6 million and a median of $199.5 million in 2024 frame the typical range for Assets.
- Annual changes were most pronounced in 2022 — Assets surged 71.85% — and 2025, when it plunged 42.13%.
- Tracing BRNS's Assets over 5 years: stood at $270.2 million in 2022, then retreated by 20.61% to $214.5 million in 2023, then retreated by 25.26% to $160.3 million in 2024, then sank by 38.77% to $98.2 million in 2025, then declined by 6.14% to $92.1 million in 2026.
- The last three Assets figures came in at $92.1 million (Q1 2026), $98.2 million (Q4 2025), and $109.2 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.47 Bn | 131.61 Bn | 2.84 Bn | 27.42 Bn |
| 2 | Regeneron Pharmaceuticals | 86.36 Bn | 78.37 Bn | 3.93 Bn | 41.73 Bn |
| 3 | Argenx Se | 65.16 Bn | 59.98 Bn | 1.37 Bn | 10.03 Bn |
| 4 | Moderna | 58.99 Bn | 53.85 Bn | 52.00 Mn | 10.96 Bn |
| 5 | BeOne Medicines | 42.08 Bn | 36.98 Bn | 1.53 Bn | 9.18 Bn |
| 6 | Alnylam Pharmaceuticals | 31.74 Bn | 28.43 Bn | 992.69 Mn | 5.56 Bn |
| 7 | BioNTech SE | 28.01 Bn | 9.61 Bn | 668.28 Mn | 25.60 Bn |
| 8 | Insmed | 27.50 Bn | 26.34 Bn | 358.27 Mn | 2.10 Bn |
| 9 | Royalty Pharma | 27.28 Bn | 26.45 Bn | - | 19.82 Bn |
| 10 | Barinthus Biotherapeutics | 25.29 Mn | 25.29 Mn | - | 81.89 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 81.89 Mn |
| Mar 31, 2026 | 92.14 Mn |
| Dec 31, 2025 | 98.17 Mn |
| Sep 30, 2025 | 109.20 Mn |
| Jun 30, 2025 | 129.56 Mn |
| Mar 31, 2025 | 142.00 Mn |
| Dec 31, 2024 | 160.33 Mn |
| Sep 30, 2024 | 188.69 Mn |
| Jun 30, 2024 | 186.75 Mn |
| Mar 31, 2024 | 199.48 Mn |
| Dec 31, 2023 | 214.51 Mn |
| Sep 30, 2023 | 229.97 Mn |
| Jun 30, 2023 | 246.13 Mn |
| Mar 31, 2023 | 261.82 Mn |
| Dec 31, 2022 | 270.21 Mn |
| Sep 30, 2022 | 275.48 Mn |
| Jun 30, 2022 | 285.06 Mn |
| Mar 31, 2022 | 286.12 Mn |
| Dec 31, 2021 | 280.72 Mn |
| Sep 30, 2021 | 256.57 Mn |